Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Zachary Frosch, Anthony Masaquel, Esprit Ma, Eric Zuk, Matthew Davis, Fadoua El Moustaid, Mei Wu, Carolina Reyes, Lourenia Cassoli, Scott Huntington

Blood (2025) 146 (Supplement 1): 2622.

https://doi.org/10.1182/blood-2025-2622

Published: 2025

Journal Articles

Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Patrick Reagan, Natasha Shamas, Anthony Masaquel, Farah Hossain, Adriano Sa, Sai Li, Yong Mun, Lara Chayab, Laura Perez, Carolina Reyes, Ashwini Shewade, Daniel Landsburg

Blood (2025) 146 (Supplement 1): 6265.

https://doi.org/10.1182/blood-2025-6265

Published: 2025

Journal Articles

Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among Medicare beneficiaries

John Vaughn, Anthony Masaquel, Carolina Reyes, Farah Hossain, Eric Zuk, Rebecca Straubing, Matthew Davis, Scott Huntington

Blood (2025) 146 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2025-4489

Published: 2025

Journal Articles

Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States

Matthew Matasar, Anthony Masaquel, Carolina Reyes, Farah Hossain, Eric Zuk, Rebecca Straubing, Matthew Davis, Scott Huntington

Blood (2025) 146 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2025-4486

Published: 2025

Journal Articles

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Ajay Major, Esprit Ma, Anthony Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Pophali, Sally Werner, Rebecca Bungay, Dominick Latremouille-Viau, Annie Guerin, Carolina Reyes, Mei Wu, Lourenia Cassoli, Pallawi Torka

Blood (2025) 146 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2025-6181

Published: 2025

Journal Articles

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs)

Zachary Frosch, Anthony Masaquel, David Fox, Carolina Reyes, Lourenia Cassoli, Dominic Lai, Kelley Myers, Cooper Bussberg, Krish Patel

Blood (2025) 146 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2025-6179

Published: 2025

Journal Articles

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

Pallawi Torka, Anthony Masaquel, Lourenia Cassoli, David Fox, Arliene Mangalindan, Ajay Major

Blood (2024) 144 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2024-198476

Published: 2024

Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2024-198451

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch

Blood (2024) 144 (Supplement 1): 782.

https://doi.org/10.1182/blood-2024-198414

Published: 2024

Journal Articles

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

David Fox, Fadoua El Moustaid, Anthony Masaquel, Katherine L Rosettie, Hazal Celik, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 5027.

https://doi.org/10.1182/blood-2024-198461

Published: 2024

Journal Articles

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

Zahra Mahmoudjafari, Danilo Di Maio, Jia Li, Katherine L. Rosettie, Anthony Masaquel

Blood (2023) 142 (Supplement 1): 3703.

https://doi.org/10.1182/blood-2023-174918

Published: 2023

Journal Articles

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis

Zahra Mahmoudjafari, Jia Li, Eric Bercaw, Hélène Parisé, Katalin Bognar, Si-Tien Wang, Anthony Masaquel

Blood (2023) 142 (Supplement 1): 7246.

https://doi.org/10.1182/blood-2023-174218

Published: 2023

Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen

Blood (2022) 140 (Supplement 1): 6645–6647.

https://doi.org/10.1182/blood-2022-157904

Published: 2022

Journal Articles

Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Justin Gatwood, Anthony Masaquel, Ryan Ross, Danny Sheinson, Farah Hossain, Jia Li, Cameron James, David Fox

Blood (2022) 140 (Supplement 1): 7906–7907.

https://doi.org/10.1182/blood-2022-157905

Published: 2022

Journal Articles

Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)

Rongrong Wang, Josh Roth, Carmen Ng, Farah Hossain, Jia Li, Anthony Masaquel

Blood (2021) 138 (Supplement 1): 3002.

https://doi.org/10.1182/blood-2021-146802

Published: 2021

Journal Articles

Factors Associated with Overall Survival in Follicular Lymphoma Patients Who Are Eligible for Maintenance Therapy

Ahmad S Halwani, MD, Kelli M Rasmussen, MS, Vikas Patil, MS, Zachary Burningham, PhD, Catherine Li, PhD, Christina Young, MA, Anthony Masaquel, PhD MPH, Kevin Henderson, PharmD, MBA, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2018) 132 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2018-99-115722

Published: 2018

Journal Articles

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Ahmad S Halwani, MD, Kelli M Rasmussen, MS, Vikas Patil, MS, Catherine Li, PhD, Christina Young, MA, Zachary Burningham, PhD, Mathias Schulz, MD MBA, Jia Li, PhD, Anthony Masaquel, PhD MPH, Mary Halloran, PharmD, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2018) 132 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2018-99-116695

Published: 2018

Journal Articles

What Are Patients' Preferences and Satisfaction Regarding Modes of Administration for the Treatment of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL)?

Mark Price, MA, MD, Arliene Ravelo, MPH, Elisa Weiss, PhD, Peggy Ann Torney, MS, Victor Gonzalez, MHC-LP, Maria Sae-Hau, PhD, Carol Mansfield, PhD, Eydith Comenencia-Ortiz, PhD, Miko Cunanan, BS, Anthony Masaquel, PhD MPH, Keith L Dawson, DNP

Blood (2018) 132 (Supplement 1): 5897.

https://doi.org/10.1182/blood-2018-99-115327

Published: 2018

Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 683.

https://doi.org/10.1182/blood.V130.Suppl_1.683.683

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs)

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)

Factors Associated with Overall Survival in Follicular Lymphoma Patients Who Are Eligible for Maintenance Therapy

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

What Are Patients' Preferences and Satisfaction Regarding Modes of Administration for the Treatment of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL)?

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only